SecBot SecBot

RHHBY

ROCHE HOLDING AG
$60.09 −1.08 (−1.77%)
Oct 26 4:00 PM ET · prev $61.17
Median target
$61.00
+2% · range $52.00–67.10
1 year
+42.8%
from $42.09 · Oct 27
30 days
+12.6%
from $53.37
52-week range
$40.15–61.17
−2% from high · low Nov 3
Avg volume 20D
1.32M
shares / day
Short interest
3.02M
+25.3%
Days to cover
1.1
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
Congress trades
1
disclosed
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/4
Strongest BULLISH The D.C. District Court granted Genentech's petition to enforce a foreign arbitration award against…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +25.3% to 3.02M shares. 1.1 days to cover.

  • TrendUPTREND

    9% above its 50-day average. New closing high $61.17 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
First Command Advisory Services, Inc.DOUBLED13,055$670.4K
Pacer Advisors, Inc.EXIT0$0.00
MAI Capital ManagementTRIM27,682$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12-month targets · 7 analysts

Price is inside the target range. Median implies +2%.Targets as of Oct 26, 2026.

Congressional trades
RHHBY trades disclosed by members of Congress, with disclosure delay.
0 members(excl. 1 subscriber-only trade) · 1 buys / 0 sells
DateMemberTypeAmountDisclosed
Sep 11, 2026🔒 Fresh data, subscribers onlyBUY

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q———$16.6B
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trial readout
🔒 Fresh data, subscribers only
Oct 25, 2026
Trial readout
🔒 Fresh data, subscribers only
Oct 25, 2026
Trial readout
🔒 Fresh data, subscribers only
Oct 26, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Oct 24, 2026
Trial readout
Results Pending: Crovalimab (Phase 2) — Completed 72d ago
Trial: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal…

Short side

FINRA· Sep 30, 2026
3,021,666
shares short
+25.3%
vs prior settlement
1.1
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Oct 23, 2026 SEC
A New Jersey federal district court issued a Markman claim construction ruling in Genentech's ANDA litigation against…
COURT-RULING — Impact 4/10
Oct 23, 2026 Event
GENENTECH, INC. et al v. SUN PHARMACEUTICAL INDUSTRIES, LTD et al
Court ruling (njd) — Docket: 2:24-cv-10567
Oct 13, 2026 SEC
The D.C. District Court granted Genentech's petition to enforce a foreign arbitration award against Novartis…
COURT-RULING — Impact 6/10
Sep 11, 2026 Congress
🔒 Fresh data, subscribers only
Aug 20, 2026 Event
COTELLIC
Supplemental Approval — Labeling — COBIMETINIB — TABLET — ORAL
Aug 14, 2026 SEC
Genentech (RHHBY) won summary judgment in D.D.C. invalidating HRSA's certification of 11 clinics as 340B covered…
COURT-RULING — Impact 6/10
Jun 30, 2026 Inst.
First Command Advisory Services, — DOUBLED
13,055 shares ($670.4K)

SecBot reports

4 filings · 2 bullish · 0 bearish · 2 neutral
All RHHBY filing & press-release reports (4)